Insider Selling: Adaptive Biotechnologies (NASDAQ:ADPT) Insider Sells $110,941.60 in Stock

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) insider Harlan Robins sold 6,160 shares of the business’s stock in a transaction dated Tuesday, June 16th. The stock was sold at an average price of $18.01, for a total value of $110,941.60. Following the completion of the transaction, the insider owned 1,405,898 shares in the company, valued at approximately $25,320,222.98. This trade represents a 0.44% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Adaptive Biotechnologies Price Performance

Shares of ADPT opened at $17.54 on Friday. The business’s fifty day moving average price is $14.85 and its 200 day moving average price is $15.59. Adaptive Biotechnologies Corporation has a 12-month low of $9.96 and a 12-month high of $20.76. The stock has a market capitalization of $2.81 billion, a PE ratio of -53.16 and a beta of 2.15.

Adaptive Biotechnologies (NASDAQ:ADPT) last released its quarterly earnings data on Tuesday, May 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.03. The business had revenue of $70.87 million during the quarter, compared to analyst estimates of $61.03 million. Adaptive Biotechnologies had a negative return on equity of 40.06% and a negative net margin of 16.82%.The business’s revenue for the quarter was up 35.1% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.20) EPS. As a group, research analysts anticipate that Adaptive Biotechnologies Corporation will post -0.47 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Adaptive Biotechnologies

A number of institutional investors and hedge funds have recently made changes to their positions in ADPT. California State Teachers Retirement System grew its holdings in Adaptive Biotechnologies by 1.0% during the 2nd quarter. California State Teachers Retirement System now owns 98,321 shares of the company’s stock worth $1,145,000 after acquiring an additional 933 shares during the period. PNC Financial Services Group Inc. increased its stake in Adaptive Biotechnologies by 6.8% during the 1st quarter. PNC Financial Services Group Inc. now owns 14,737 shares of the company’s stock valued at $205,000 after purchasing an additional 941 shares in the last quarter. Captrust Financial Advisors raised its holdings in shares of Adaptive Biotechnologies by 7.6% in the 2nd quarter. Captrust Financial Advisors now owns 15,762 shares of the company’s stock worth $184,000 after acquiring an additional 1,119 shares during the last quarter. Assetmark Inc. raised its stake in shares of Adaptive Biotechnologies by 46.4% in the first quarter. Assetmark Inc. now owns 4,421 shares of the company’s stock worth $61,000 after purchasing an additional 1,401 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. lifted its stake in Adaptive Biotechnologies by 26.0% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,419 shares of the company’s stock valued at $120,000 after acquiring an additional 1,532 shares in the last quarter. Institutional investors own 99.17% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on ADPT shares. BTIG Research reissued a “buy” rating and issued a $22.00 price target on shares of Adaptive Biotechnologies in a research note on Wednesday. Wall Street Zen downgraded shares of Adaptive Biotechnologies from a “buy” rating to a “hold” rating in a research note on Saturday, March 7th. Guggenheim reaffirmed a “buy” rating and set a $21.00 price objective on shares of Adaptive Biotechnologies in a research report on Wednesday, May 6th. TD Cowen raised their target price on Adaptive Biotechnologies from $19.00 to $21.00 and gave the company a “buy” rating in a report on Wednesday, May 6th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research report on Monday, April 20th. Five equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $20.33.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.